{"title":"SGLT2抑制剂及其在糖尿病中的作用","authors":"G. Himabindhu","doi":"10.35248/2161-1017.20.9.313","DOIUrl":null,"url":null,"abstract":"SGLT2 is a low-affinity, and high capacity glucose transporter located in the kidneys (proximal tubule). It is responsible for 90% of glucose reabsorption. Inhibition of SGLT2 leads to decrease in blood glucose due to increase in renal glucose excretion. The mechanism of action of this newest class of drugs also offers further glucose control by allowing increased insulin sensitivity and uptake of glucose in the muscle cells, decreased gluconeogenesis and improved first phase insulin release from the beta cells.","PeriodicalId":11670,"journal":{"name":"Endocrinology and Metabolic Syndrome","volume":"50 1","pages":"1-1"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"SGLT2 Inhibitors and Its Role in Diabetes\",\"authors\":\"G. Himabindhu\",\"doi\":\"10.35248/2161-1017.20.9.313\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"SGLT2 is a low-affinity, and high capacity glucose transporter located in the kidneys (proximal tubule). It is responsible for 90% of glucose reabsorption. Inhibition of SGLT2 leads to decrease in blood glucose due to increase in renal glucose excretion. The mechanism of action of this newest class of drugs also offers further glucose control by allowing increased insulin sensitivity and uptake of glucose in the muscle cells, decreased gluconeogenesis and improved first phase insulin release from the beta cells.\",\"PeriodicalId\":11670,\"journal\":{\"name\":\"Endocrinology and Metabolic Syndrome\",\"volume\":\"50 1\",\"pages\":\"1-1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinology and Metabolic Syndrome\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2161-1017.20.9.313\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology and Metabolic Syndrome","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2161-1017.20.9.313","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
SGLT2 is a low-affinity, and high capacity glucose transporter located in the kidneys (proximal tubule). It is responsible for 90% of glucose reabsorption. Inhibition of SGLT2 leads to decrease in blood glucose due to increase in renal glucose excretion. The mechanism of action of this newest class of drugs also offers further glucose control by allowing increased insulin sensitivity and uptake of glucose in the muscle cells, decreased gluconeogenesis and improved first phase insulin release from the beta cells.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
